[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-tachycardia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-tachycardia":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,46,60,83,105,131,163,187,223,244,265,290,315,341,365,390,411,431,456,481,511,532,559,580,610],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054135","parasternal-extravascular-icd-system-pivotal-clinical-investigation-alarion-ev-study-100054135",false,"NCT07324031","Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study","ALARION EV","Inclusion Criteria:\n\n1. At least 18 years old\n2. Class I or IIa indication for implantation of an ICD according to the ACC\u002FAHA\u002FHRS Guidelines or ESC guidelines\n\nExclusion Criteria:\n\n1. Patients who cannot read or write\n2. Expected survival \\\u003C 1 year\n3. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period\n4. Participation in any concurrent clinical study without prior approval from the Sponsor\n5. Inability or unwillingness to provide informed consent to participate in the study\n6. Any known circumstances which may prevent the completion of protocol testing and data collection through the 6-month follow-up visit\n7. Circumstances that may prevent data collection or completion of specified follow-up visits\n8. Allergies to any device materials listed in the Instructions for Use (IFU)\n9. Contraindication for temporary suspension of oral\u002Fsystemic anticoagulation\n10. Known history of lung disease with FEV1 \\\u003C 1.0 Liter\n\n    Device Related:\n11. Implanted with or planned implantation of any device which delivers current in the body that may interfere with therapy delivery, including, but not limited to a pacemaker, LVAD or neurostimulator\n12. Implanted with a subcutaneous ICD lead, subcutaneous coils\u002Farrays, epicardial patches or epicardial pace\u002Fsense leads\n13. Any known need for MRI prior to approval of MRI conditional labeling\n\n    Anatomy Related:\n14. Known structural abnormalities of the heart that may increase risk of the Parasternal EV-ICD System procedure\n15. Known obstructed or restricted pathway into the mediastinum for the Atala™ lead\n16. Prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium, including sternotomy of any type\n17. Known significant anatomic derangement of or within the thorax (e.g., pectus excavatum, significant scoliosis)\n18. History of thoracic radiation therapy or other medical treatments\u002Fconditions which may complicate the Parasternal EV-ICD System implant procedure\n19. Known adhesions in the thorax or history of medical treatments, surgeries or conditions that increase the potential for adhesions in the thorax\n20. Surgically corrected congenital heart disease (not including catheter-based procedures)\n\n    Cardiac Related:\n21. Indication for permanent bradycardia pacing or cardiac resynchronization therapy\n22. Decompensated heart failure\n23. Currently on inotropic therapy\n24. Known history of pericardial disease, pericarditis or mediastinitis\n25. Risk factors associated with defibrillation testing:\n\n    * Severe aortic stenosis\n    * Current Intracardiac LA or LV thrombus\n    * Severe proximal three-vessel or left main coronary artery disease without revascularization\n    * Hemodynamic instability\n    * Unstable angina\n    * Recent stroke or transient ischemic attack (within the last 3 months)\n    * Known inadequate external defibrillation\n    * LVEF \\\u003C 20% (most recent assessment; must be within 180 days of consent)\n    * LVEDD \\>70 mm (most recent assessment; must be within 180 days of consent)","ALL","18 Years",{"count":20,"type":21},280,"ESTIMATED","INTERVENTIONAL",[24],"NA","The ALARION EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of this pivotal study is to generate evidence of safety and effectiveness to apply for regulatory approvals for commercialization of the Parasternal EV-ICD System.\n\nThe objective of the study is to demonstrate safety and effectiveness of the Parasternal EV-ICD System through 6-months.",[27,28,29],"Ventricular Arrythmia","Ventricular Fibrillation","Ventricular Tachycardia",[31,32],"Ventricular Defibrillation","Extravascular","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-07-02",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"AtaCor Medical, Inc.","INDUSTRY",35,{"id":47,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":25,"conditions":50,"keywords":51,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":59,"locationsCount":4},"100617854",{"count":20,"type":21},[24],[27,28,29],[31,32],"NOT_YET_RECRUITING","2026-06-26",{"date":55,"type":37},"2026-06-30",{"date":57,"type":21},"2026-07-01",{"date":41,"type":21},{"name":43,"class":44},{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":22,"phases":69,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":74,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100475998","ventricular-tachycardia-mechanisms-100475998","NCT05478213","Ventricular Tachycardia Mechanisms","Ventricular Tachycardia Substrate Mechanisms Revealed by Local Repolarization and Conduction Parameters","Inclusion Criteria:\n\n* Diagnosis of ischemic cardiomyopathy\n* Single or dual chamber implantable cardioverter-defibrillator (ICD)\n\nExclusion Criteria:\n\n* Non-Ischemic cardiomyopathy\n* Contraindication to catheter ablation\n* Severe peripheral arterial disease or medical condition that prohibit arterial access\n* Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization",{"count":68,"type":21},10,[24],"The purpose of this study is to understand why certain hearts have ventricular arrhythmias and help identify areas of the heart that cause arrhythmias. There is still a significant gap in understanding why ventricular arrhythmias occur. This study will examine the electrical properties of the heart tissue to understand how these arrhythmias occur, and hopefully identify areas that might lead to ventricular arrhythmias. The hope is that studying this might be able to improve outcomes during ventricular tachycardia (VT) ablations.",[29],[73],"Ventricular tachycardia ablation",{"date":55,"type":37},{"date":76,"type":37},"2022-10-25",{"date":78,"type":21},"2027-05",{"name":80,"class":81},"Emory University","OTHER",3,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":22,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100637846","validation-of-ecg-based-ventricular-arrhythmia-localization-algorithms-in-patients-with-repaired-tetralogy-of-fallot-100637846","NCT07607821","Validation of ECG-Based Ventricular Arrhythmia Localization Algorithms in Patients With Repaired Tetralogy of Fallot","Validation of ECG-Based Ventricular Arrhythmia Localization Algorithms in Patients With Repaired Tetralogy of Fallot: A Prospective Pace Mapping Study","Inclusion Criteria:\n\n* Adult patients \\>\u002F= 18 years with repaired tetralogy of Fallot with pulmonary stenosis scheduled for clinically-indicated diagnostic electrophysiology (EP) study.\n\nExclusion Criteria:\n\n* Dextrocardia or mesocardia.\n* Double outlet right ventricle.\n* Tetralogy of Fallot with pulmonary atresia.\n* Contraindication to femoral arterial access.\n* Mechanical aortic prosthesis.\n* Inability to provide informed consent.",{"count":91,"type":21},30,[24],"Doctors use patterns on heart rhythm tracings (ECGs) to predict where abnormal heart rhythms originate, but these prediction methods were developed in people with normal heart structure. Patients with repaired Tetralogy of Fallot have hearts that developed differently, and cardiologists do not know if these prediction methods work accurately for them. In this study, the investigators will test whether three commonly used prediction methods work in Tetralogy of Fallot patients by pacing the heart from known locations during an already-scheduled heart procedure and comparing the predicted location to the actual location. Participation adds approximately 15 minutes to the procedure and does not require additional visits. The results will help cardiologists understand whether current methods can be trusted when planning treatments for abnormal heart rhythms in this patient population, or whether new prediction methods need to be developed.",[95,29],"Tetralogy of Fallot (TOF)","2026-06-04",{"date":98,"type":37},"2026-06-05",{"date":100,"type":21},"2026-07",{"date":102,"type":21},"2027-07",{"name":104,"class":81},"Boston Children's Hospital",{"id":106,"slug":107,"hasResults":12,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100538683","international-multicenter-project-comparing-radiofrequency-ablation-versus-implantable-defibrillator-after-well-tolerated-ventricular-tachycardia-in-ischemic-heart-disease-with-minimally-impaired-ejection-fraction-100538683","NCT06294028","International Multicenter Project Comparing Radiofrequency Ablation Versus Implantable Defibrillator After Well-tolerated Ventricular Tachycardia in Ischemic Heart Disease With Minimally Impaired Ejection Fraction","VIVA","Inclusion Criteria:\n\n* ischemic heart disease with history of infarction - LVEF\\> 35% (measured by MRI)\n* sustained monomorphic ventricular tachycardia - without history of syncope or cardiac arrest -\n* having signed informed consent\n* affiliated to a social security system\n\nExclusion Criteria:\n\n* transient regressive cause of ventricular tachycardia\n* recent myocardial infarction (\\\u003C2 months)\n* ventricular tachycardia by reentry from branch to branch\n* serious conduction disturbances (with indication of stimulation)\n* contraindication to the implantation of a defibrillator or to the performance of an ablation (life expectancy \\\u003C1 year, relevant comorbidities)\n* pregnancy\n* age \\\u003C18 years\n* Patient under legal protection, guardianship or curatorship","90 Years",{"count":114,"type":21},268,[24],"Evidence for the usefulness of the defibrillator in cases of preserved left ventricular ejection fraction and well-tolerated ventricular tachycardia (without cardiocirculatory arrest or syncope) is lacking, as no previous trials have included such patients. Additionally, sudden death in this particular population is low compared to other subgroups of patients with malignant ventricular arrhythmias.\n\nOn the other hand, numerous recent retrospective data show that ablation of ventricular tachycardia can reduce mortality, and also clearly reduces the number of recurrences in prospective studies.\n\nFinally, a very low rate of sudden death was observed in a multicenter European retrospective study that we conducted, including patients with well-tolerated ventricular tachycardia in structural heart disease with minimally impaired ejection fraction and benefiting from ablation without implantation of defibrillator.",[118,29],"Ischemic Heart Disease",[120],"Ablation","2026-05-28",{"date":123,"type":37},"2026-06-01",{"date":125,"type":37},"2024-06-12",{"date":127,"type":21},"2029-12-31",{"name":129,"class":81},"University Hospital, Toulouse",1,{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100639770","safety-and-effectiveness-of-the-sphere-9-catheter-and-affera-ablation-system-for-the-treatment-of-ventricular-tachycardia-sphere-vt-100639770","NCT07585968","Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)","Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia","Inclusion Criteria:\n\n1. Prior myocardial infarction (MI).\n2. At least one episode of sustained (continuous for \\>30 seconds or requiring ICD intervention for termination) monomorphic ventricular tachycardia within the 6 months prior to enrollment.\n3. Recurrence of sustained ventricular tachycardia despite Class I or III antiarrhythmic drug therapy or ICD intervention.\n4. Implanted with an implantable cardiac defibrillator (ICD) or CRT-D for at least 2 months prior to the ablation procedure.\n5. Age 18 through 85 years old.\n6. Willing and able to provide informed consent.\n7. Willing and able to comply with all pre-, post-, and follow-up testing requirements.\n\nExclusion Criteria:\n\n1. Incessant VT necessitating hemodynamic support prior to the ablation procedure.\n2. Unstable polymorphic VT or ventricular fibrillation (VF).\n3. Idiopathic VT or VT of non-ischemic cardiomyopathy.\n4. VT secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause (e.g., drug-induced arrhythmia).\n5. VT or VF thought to be from channelopathies.\n6. More than two prior VT ablations at any time, more than one prior VT ablation within 12 months prior to the ablation procedure, or any VT ablation within 4 weeks prior to the ablation procedure.\n7. Sarcoidosis.\n8. Hypertrophic cardiomyopathy, except when due to an apical aneurysm.\n9. Unstable angina.\n10. Active myocardial ischemia.\n11. Type 1 myocardial infarction within 2 months (60 days) prior to the ablation procedure.\n12. Any percutaneous coronary intervention performed in a setting of unstable angina or acute MI (STEMI or non-STEMI) within 2 months (60 days) prior to the ablation procedure. Note: elective PCI performed during elective angiogram would be excluded only if occurring within 30 days prior to the ablation procedure.\n13. Any cardiac surgery within 2 months (60 days) prior to the ablation procedure. Note: ICD lead implant\u002Freplacement falls under this exclusion, but ICD generator-only replacement does not.\n14. Left ventricular ejection fraction (LVEF) \\\u003C15%.\n15. NYHA Class IV heart failure.\n16. Decompensated heart failure.\n17. Extravascular ICD (EV-ICD) or subcutaneous ICD (S-ICD)\n18. Currently receiving support, or anticipated to receive support prior to the index ablation procedure, via extracorporeal membrane oxygenation (ECMO).\n19. Circulatory\u002Fventricular assist device (VAD; surgical or percutaneous) implanted, planned or required for the procedure.\n20. Severe aortic or mitral stenosis, or severe aortic or mitral regurgitation.\n21. Presence of prosthetic valve in the aortic or mitral valve.\n22. Patients with advanced COPD (on home oxygen).\n23. Presence of intracardiac tumor or other abnormality that precludes vascular access, catheter introduction, or manipulation.\n24. Thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the index ablation procedure or with neurologic deficit.\n25. Left atrium (LA) or left ventricle (LV) intracardiac thrombus on imaging.\n26. Severe bleeding, clotting or thrombotic disorder, or thrombocytopenia (defined as platelet count \\\u003C80,000).\n27. Contraindication to anticoagulation.\n28. End-stage renal disease (requiring dialysis).\n29. Acute illness, active infection, or sepsis.\n30. Life expectancy less than 12 months.\n31. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence.\n32. Body mass index \\>45 kg\u002Fm2.\n33. Known ongoing drug or alcohol dependency.\n34. Current or anticipated participation in any other ongoing study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.\n35. Vulnerable subjects (such as a prisoner, handicapped or mentally disabled person, or person under tutelage or guardianship).\n36. Any other condition that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would pose a significant hazard to the subject if an ablation procedure were performed.","85 Years",{"count":140,"type":21},260,[24],"Sphere VT is a prospective, multi-center, single-arm, unblinded pivotal clinical study. Adult subjects with recurrent, sustained, monomorphic ventricular tachycardia (MMVT) due to prior myocardial infarction (MI) will be enrolled and treated with the Sphere-9 Catheter and Affera Ablation System.",[29],[145,146,147,148,149,150,151,152,153],"Recurrent sustained scar-related monomorphic ventricular tachycardia","Ventricular tachycardia","Arrhythmias, Cardiac","Heart Diseases","Cardiovascular Diseases","Pathologic Processes","Ischemic heart disease","Patient with Implantable Cardioverter Defibrillator (ICD)","Ischemic cardiomyopathy","2026-05-07",{"date":156,"type":37},"2026-05-14",{"date":158,"type":21},"2026-06",{"date":160,"type":21},"2028-09",{"name":162,"class":44},"Medtronic Cardiac Ablation Solutions",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":170,"targetDuration":172,"studyType":173,"phases":4,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":130},"100560341","defining-the-risk-of-ventricular-tachycardia-in-genetic-cardiomyopathies-100560341","NCT06575881","Defining the Risk of Ventricular Tachycardia in Genetic Cardiomyopathies","Defining the Risk of Ventricular Tachycardia in Genetic Forms of Early-onset Atrial Fibrillation","Inclusion Criteria:\n\n* Adults aged 18 and older\n* Diagnosed with AF, frequent PVCs, or VT before age 60\n* Scheduled for catheter-based AF ablation (de-novo or repeat) OR catheter-based PVC ablation OR catheter-based VT ablation\n* Able to provide written, informed consent\n* P\u002FLP variant in TTN or other CM gene (cases) or identified as a genotype-negative control.\n\nExclusion Criteria:\n\n* Diagnosed with a genetic CM or arrhythmia syndrome prior to ablation procedure\n* VUS in 'possibly pathogenic' subgroup (control group only)\n* Previous PVC or VT ablation\n* LVEF \\\u003C20%\n* Prosthetic mitral or aortic valve\n* Contraindication to heparin\n* Prior myocardial infarction",{"count":171,"type":21},200,"3 Years","OBSERVATIONAL","The goal of this observational study is to determine if electrophysiologic mapping and cardiac MRI can help identify patients that have genetic forms of cardiomyopathy that are at high risk for development of dangerous ventricular arrhythmias.\n\nThe investigators aim to study:\n\n1. the prevalence and mechanism of inducible ventricular tachycardia\n2. pace-mapping to define the site of origin of ventricular arrhythmias\n3. voltage mapping to define low voltage scar substrate in the basal LV to determine the risk of development of ventricular arrhythmias in patients with genetic forms of cardiomyopathy.\n\nParticipants will undergo cardiac MRI before their scheduled procedure and voltage mapping during their scheduled procedure as part of data collection.",[176,29,177],"Atrial Fibrillation","Premature Ventricular Contraction","2026-04-30",{"date":180,"type":37},"2026-05-06",{"date":182,"type":37},"2023-12-13",{"date":184,"type":21},"2029-12",{"name":186,"class":81},"Vanderbilt University Medical Center",{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":173,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":222},"100289553","mayo-avc-registry-and-biobank-100289553","NCT03049254","Mayo AVC Registry and Biobank","Identification of Novel Genetic Variants and Biomarkers of Disease Progression in Arrhythmogenic Cardiomyopathy","Inclusion Criteria:\n\n* Patients with a diagnosis of a non-MI SCA who survived\n* Patients with a non-MI SCD\n* Patient with a SCA associated with seizures, epilepsy, syncope, drowning and near-drowning, where a cardiomyopathy is suspected\n* Family member of a patient diagnosed with primary cardiomyopathy (including HCM, idiopathic DCM, AVC)\n\nExclusion Criteria:\n\n* Patients with a clear, unambiguous known cause of SCA or SCD such as myocardial infarction or heart failure secondary to ischemic heart disease\n* Significant coronary artery disease (Epicardial coronary artery stenosis \\>50%) which can explain degree of LV dysfunction\n* Those unwilling to provide written consent or assent",true,{"count":196,"type":21},1000,"Arrhythmogenic ventricular cardiomyopathy (AVC) is a genetic condition which affects the heart and can lead to heart failure and rhythm problems, of which, sudden cardiac arrest or death is the most tragic and dangerous. Diagnosis and screening of blood-relatives is very difficult as the disease process can be subtle, but sufficient enough, so that the first event is sudden death.\n\nThe Mayo Clinic AVC Registry is a collaboration between Mayo Clinic, Rochester, USA and Papworth Hospital, Cambridge University Hospitals, Cambridge, UK. The investigators aim to enroll patients with a history of AVC or sudden cardiac death which may be due to AVC, from the US and UK. Family members who are blood-relatives will also be invited, including those who do not have the condition. Data collected include symptoms, ECG, echocardiographic, MRI, Holter, loop recorder, biopsies, exercise stress testing, blood, buccal and saliva samples.\n\nObjectives of the study:\n\n1. Discover new genes or altered genes (variants) which cause AVC\n2. Identify biomarkers which predict (2a) disease onset, (2b) disease progression, (2c) and the likelihood of arrhythmia (ventricular, supra-ventricular and atrial fibrillation)\n3. Correlate genotype with phenotype in confirmed cases of AVC followed longitudinally using clinical, electrocardiographic and imaging data.\n4. Characterize desmosomal changes in buccal mucosal cells with genotype and validate with gold-standard endomyocardial biopsies",[199,200,148,149,201,202,203,204,205,206,207,208,209,210,211,29,212],"Arrhythmogenic Right Ventricular Cardiomyopathy","Cardiomyopathies","Sudden Cardiac Arrest","Sudden Cardiac Death","Arrhythmogenic Right Ventricular Dysplasia","Arrhythmogenic Ventricular Cardiomyopathy","Familial Dilated Cardiomyopathy","Cardiovascular Abnormalities","Sarcoidosis","Cardiac Arrhythmia","Cardiac Sarcoidosis","Myocarditis","Inflammatory Cardiomyopathy","Right Ventricular Outflow Tract Ventricular Tachycardia","2026-04-22",{"date":215,"type":37},"2026-04-27",{"date":217,"type":37},"2018-02-09",{"date":219,"type":21},"2027-03",{"name":221,"class":81},"Mayo Clinic",2,{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":130},"100485280","randomized-assessment-of-tcms-for-vt-storm-100485280","NCT05599022","Randomized Assessment of TcMS for VT Storm","Randomized Assessment of the Efficacy of Transcutaneous Magnetic Stimulation in Patients With Ventricular Tachycardia Storm","Inclusion Criteria:\n\n* ≥3 episodes of sustained VT or appropriate ICD therapies within 24 hours despite the use of at least one antiarrhythmic drug\n\nExclusion Criteria:\n\n* Plan for catheter ablation of VT in the next 24 hours\n* Pregnancy\n* Contraindication to TcMS (i.e. implantable ventricular assist device, metal implanted in the head or neck \\[except the mouth\\], implanted medication pumps, cochlear implant, implanted brain stimulator, ocular implant, history of malignancy in the neck)",{"count":231,"type":21},60,[24],"Three-arm randomized clinical trial comparing two strategies of TcMS to sham stimulation in patients with VT storm. The hypothesis of the study is that TcMS will reduce the burden of VT in the 24 hours after randomization compared to sham stimulation and that TcMS with theta burst stimulation (TBS) will be more effective at reducing VT burden than low frequency TcMS.",[29],"2026-04-16",{"date":237,"type":37},"2026-04-21",{"date":239,"type":37},"2023-05-22",{"date":241,"type":21},"2028-10",{"name":243,"class":81},"University of Pennsylvania",{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":130},"100561688","cardiac-radioablation-for-vt-100561688","NCT06593418","Cardiac Radioablation for VT","A Phase I\u002FII Study of Cardiac Radioablation for Refractory Ventricular Tachycardia","Inclusion Criteria:\n\n* Participants must be 18 years or older.\n* Automatic implanted cardiac defibrillator present.\n* VT is monomorphic with at least two episodes of VT within an eight week (56 day) period as recorded by an AICD or heart failure related to VT or VT storm.\n* Ejection fraction ≥20%.\n* At least one previous cardiac ablation for VT.\n* VT refractory despite antiarrhythmic medications.\n* Likely to live for 12 months in the absence of VT.\n* AICD in a position in the chest RT to be given without direct radiation.\n* Woman of reproductive age must ensure that she won't become pregnant or breastfeed at the time of RT.\n* The participant has no contraindications to a Cardiac MRI as per routine Cardiology practice.\n\nExclusion Criteria:\n\n* Class IV heart failure\n* Abandoned leads.\n* Prior radiation therapy to the chest or upper abdomen.\n* Interstitial lung disease.",{"count":252,"type":21},24,[24],"The goal of this interventional study is to determine the minimum dose necessary for successful cardiac radioablation of refractory ventricular tachycardia (VT) and to study the utility of target volume definition using Delayed Enhancement Cardiac MRI (DE-CMR) .",[29,256],"Myocardial Infarction","2026-04-15",{"date":259,"type":37},"2026-04-20",{"date":100,"type":21},{"date":262,"type":21},"2028-01",{"name":264,"class":81},"Corewell Health East",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":22,"phases":274,"briefSummary":275,"conditions":276,"keywords":277,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":130},"100545645","vt-cryoablation-system-post-market-clinical-follow-up-pmcf-study-100545645","NCT06384599","VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study","Adagio Medical VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study","Inclusion Criteria:\n\n* IC 1 Male or female the ages of ≥ 18 years\n* IC 2 Planned ablation procedure according to the indication for use of the Adagio VT Cryoablation System\n* IC 3 Subject willing to comply with study requirements and give informed consent\n* IC4 Subject has or will be receiving an ICD prior to hospital discharge\n\nExclusion Criteria:\n\n* EC 1 In the opinion of the investigator, any known contraindication to a ventricular tachycardia procedure with the Adagio VT Cyroablation System as indicated in the device Instructions For Use (IFU)\n* EC 2 Subject is enrolled in a study that has not been approved for concurrent enrollment by the sponsor\n* EC 3 Any other condition that, in the judgement of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than six months, extensive travel away from the research center)",{"count":273,"type":21},130,[24],"The PMCF is a prospective, single-arm, multi-center, controlled study of up to 130 patients designed to collect safety and performance data regarding the use of the Adagio VT Cryoablation System in the treatment of recurrent ventricular tachycardia.",[29],[278,279,280],"Monomorphic Ventricular Tachycardia","VT","Cryoablation","2026-04-06",{"date":283,"type":37},"2026-04-09",{"date":285,"type":21},"2026-09-01",{"date":287,"type":21},"2027-09-01",{"name":289,"class":44},"Adagio Medical",{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":222},"100608434","real-time-intracardiac-echocardiography-for-ventricular-arrhythmia-ablation-100608434","NCT07201506","Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation","Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation: A Randomized Controlled Trial","REAL-ICE","Inclusion Criteria:\n\n* Patients (≥18y) undergoing a premature ventricular contraction or ventricular tachycardia ablation.\n\nExclusion Criteria:\n\n* Origin of ventricular arrhythmia with high likelihood in the right ventricular outflow tract (left-bundle-inferior axis, \\>V4 transition precordially)\n* Primary epicardial ablation planned\n* Congenital heart disease\n* Presence of a mechanical tricuspid valve prosthesis\n* Unwilling or unable to comply fully with study procedures and followup",{"count":299,"type":21},70,[24],"This study is investigating whether using ultrasound directly inside the heart during ablation of heart rhythm disorders in the ventricles can reduce radiation exposure for patients.\n\nDuring an ablation, catheters are guided through the heart to treat the abnormal electrical signals. Usually, X-ray imaging (fluoroscopy) is used to see where the catheters are, which exposes both patients and hospital staff to radiation.\n\nThe study is randomized and controlled: half of the participants will have the ablation with ultrasound inside the heart, and the other half will have the standard ablation without ultrasound during the procedure. The main goal is to compare the amount of X-ray time used during the procedure. Secondary goals are to look at safety, effectiveness, and the total procedure time.\n\nPatients with premature ventricular contractions or ventricular tachycardia can take part. A total of 70 people will be included, 35 in each group. Using ultrasound inside the heart makes it possible to see the catheters and heart structures directly, so many steps can be done without X-rays. This could make ablations safer and reduce radiation exposure.\n\nThe study is being carried out at Inselspital, Bern University Hospital, and at University Hospital Basel. All steps are standardized and data are collected carefully. The results will show whether ultrasound during ablations can significantly reduce radiation and make ablations more efficient and safer.",[303,304,29,305],"Ablation of Arrhythmias","Premature Ventricular Contractions","Ventricular Arrhythmia","2026-03-26",{"date":308,"type":37},"2026-04-01",{"date":310,"type":37},"2026-03-25",{"date":312,"type":21},"2027-06-30",{"name":314,"class":81},"Insel Gruppe AG, University Hospital Bern",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":327,"conditions":328,"keywords":330,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":130},"100478536","phase-2-venous-ethanol-for-ventricular-tachycardia-100478536","NCT05511246","Venous Ethanol for Ventricular Tachycardia","Venous Ethanol for Ischemic Left Ventricular Tachycardia","VELVET","Inclusion Criteria:\n\n* Male and female, ages of 18 and 85 years and with a prior ICD implant\n* Diagnosed with ischemic cardiomyopathy: Prior myocardial infarction (pathological Q waves or imaging evidence of regional myocardial akinesis\u002Fthinning in the absence of a non-ischemic cause)\n* One of the following VT events (within last 6 months): a) ≥3 episodes of VT treated with anti-tachycardia pacing (ATP) or anti-arrhythmic drugs; b) ≥1 appropriate ICD shocks; c) ≥3 VT episodes within 24 hr; d) sustained VT below detection rate of the ICD documented by EKG\u002Fcardiac monitor\n* Patients deemed candidates for RF ablation of VT\n* Able and willing to comply with pre-, post-, and follow-up requirements\n* Willing to sign the informed consent\n\nExclusion Criteria:\n\n* Serum creatinine \\>1.5 mg\u002FdL, or creatinine clearance \\\u003C30 ml\u002Fmin\n* Left ventricular (LV) ejection fraction ≤10%\n* Mobile LV thrombus on echocardiography\n* Absence of vascular access to the LV\n* Disease process likely to limit survival to \\\u003C12 months\n* New York Heart Association class IV heart failure\n* Cardiac surgery within the past 2 months (unless VT was incessant),\n* Acute coronary syndrome in the past 2 months (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on EKG)\n* Another reversible cause of VT (e.g. electrolyte abnormalities, drug-induced arrhythmia)\n* Severe aortic stenosis or mitral regurgitation with a flail leaflet\n* Pregnancy\n* Unwilling or unable to provide informed consent\n* Covid-19 positive testing within 14 days of randomization procedure\n* Enrolled, or planning to get enrolled, in another research study during his\u002Fher participation on the Velvet trial",{"count":324,"type":21},156,[326],"PHASE2","Comparative effectiveness randomized clinical trial, comparing endocardial radiofrequency ablation alone vs radiofrequency ablation combined with venous ethanol in patients with ischemic ventricular tachycardia -Venous Ethanol for Left Ventricular Ischemic Ventricular Tachycardia -VELVET clinical trial",[29,329],"Ischemic Cardiomyopathy",[146,331,332,120],"Coronary veins","Ethanol",{"date":334,"type":37},"2026-03-30",{"date":336,"type":37},"2023-04-12",{"date":338,"type":21},"2028-12-12",{"name":340,"class":81},"The Methodist Hospital Research Institute",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":130},"100544656","deep-substrate-mapping-versus-activation-mapping-for-vt-100544656","NCT06371729","DEEP Substrate Mapping Versus Activation Mapping for VT","Substrate-based DEEP Mapping Versus Activation Mapping: A Prospective Randomized Multicenter Study","Inclusion Criteria:\n\n* Patients with an implanted ICD (all brands)\n* Patients with the indication for Ventricular Tachycardia Ablation (both first and redo procedures), supported by EnSite 3D mapping system, for the following disease aetiologies: previous MI, myocarditis, arrhythmogenic right\u002Fleft ventricular dysplasia\n* Age: 18 years or more.\n* A participant is willing and able to give informed consent for participation in the trial and is available to respect the assessments described in the protocol and informed consent form.\n\nExclusion Criteria:\n\n* Contraindication to anticoagulants.\n* Presence of thrombi.\n* Presence of Mitral and Aortic prosthetic valve.\n* Recent (less than 3 months) myocardial infarction, unstable angina, or Coronary Artery Bypass.\n* Ventricular Tachycardia caused by reversible pathology.\n* Life expectancy less than 1 year, according to the investigator.\n* Contraindications to the use of ablation\u002Fdiagnostic catheters or to cardiac catheterization.\n* Female participant who is pregnant, lactating, or planning pregnancy during the course of the trial.",{"count":349,"type":21},222,[24],"Substrate-based DEEP mapping and activation mapping are two of the main techniques used for guiding ventricular tachycardia (VT) ablation. There is no data comparing directly the extent of applicability, procedural results, and the long-term outcomes between the two mapping strategies.This randomized clinical trial aims to test whether activation mapping is superior to DEEP mapping to reduce ventricular tachycardia recurrence.\n\nThe primary endpoint of the study is to compare recurrence-free survival rate of ventricular tachycardia at 12 months and procedural feasibility of substrate-based DEEP mapping versus activation mapping for VT ablation.",[29],[354,355],"DEEP substrate mapping","Activation mapping","2026-03-24",{"date":358,"type":37},"2026-03-27",{"date":360,"type":37},"2024-06-13",{"date":362,"type":21},"2027-06",{"name":364,"class":81},"IRCCS Ospedale San Raffaele",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":173,"phases":4,"briefSummary":374,"conditions":375,"keywords":380,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":130},"100503894","coronary-flow-during-rapid-heart-rates-100503894","NCT05841199","Coronary Flow During Rapid Heart Rates","Coronary Epicardial and Microcirculatory Determinants of Ventricular Tachycardia Tolerability","VT flow","Inclusion Criteria:\n\n* Able to give valid consent\n* Referred for coronary angiography or coronary angioplasty\n* Suitable for percutaneous physiological interrogation and PCI when clinically indicated\n\nExclusion Criteria:\n\n* Unable to give valid consent\n* Pregnant or breastfeeding women\n* Unstable coronary artery disease (acute coronary syndrome)\n* Severe multivessel coronary artery disease suitable for coronary artery bypass grafting\n* Severe heart valve disease\n* Severe (NYHA IV) heart failure",{"count":299,"type":21},"The goal of this observational study is to learn about the factors which determine how well ventricular tachycardia (VT) is tolerated. The main questions it aims to answer are:\n\n1. What impact does coronary artery disease have on the ability for a patient to tolerate VT?\n2. Does treatment of coronary artery disease with stents improve the tolerability of VT?\n\nParticipants who are undergoing a clinically indicated coronary angiogram or coronary angioplasty procedure will have measurements of blood pressure, coronary pressure and coronary flow made during pacing at a range of heart rates.",[29,376,377,378,379],"Coronary Artery Disease","Heart Failure","Coronary Microvascular Dysfunction","Coronary Microvascular Disease",[29,376,377,378,379,381,382],"Percutaneous Coronary Intervention","Implantable Cardioverter Defibrillator",{"date":358,"type":37},{"date":385,"type":37},"2023-08-01",{"date":387,"type":21},"2026-06-02",{"name":389,"class":81},"Imperial College London",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":22,"phases":399,"briefSummary":400,"conditions":401,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":409,"locationsCount":130},"100374953","cohort-study---sbrt-for-vt-radioablation-100374953","NCT04162171","Cohort Study - SBRT for VT Radioablation","Noninvasive Cardiac Radioablation for Ventricular Tachycardia","Inclusion Criteria:\n\n* Structural heart disease: ischemic or non-ischemic cardiomyopathy diagnosed with cardiac imaging demonstrating either segmental myocardial dysfunction, or presence of scar, AND\n* One of the following monomorphic VT events despite prior attempted catheter ablation (or contraindication for ablation), AND despite treatment with a class III antiarrhythmic drug (contraindicated, ineffective or not tolerated): A: Documented sustained monomorphic VT terminated by pharmacologic means, DC cardioversion or manual ICD Therapy. B: ≥3 episodes of monomorphic VT treated with antitachycardia pacing (ATP), at least one of which was symptomatic C: ≥ 5 episodes of monomorphic VT treated with antitachycardia pacing (ATP) regardless of symptoms D: ≥1 appropriate ICD shocks, E: ≥3 monomorphic VT episodes within 24 hours \\*\\* VT events must be confirmed by ECG\u002Fmonitor or ICD download.\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent\n* Have received prior radiotherapy to the likely treatment field\n* Inotrope-dependent heart failure or an anticipated life-expectancy of \\\u003C 1 year in the absence of VT\n* Presenting arrhythmia: polymorphic VT or ventricular fibrillation (VF)\n* Pregnancy\n* Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days thought to be due to acute coronary arterial thrombosis, or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia.",{"count":398,"type":21},12,[24],"Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical \"short circuit\" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. Current treatment for VT consists of either implantable defibrillators (ICDs), suppressive drug therapy, catheter ablation or a combination of all 3.\n\nImplantable Defibrillators (ICDs) reduce sudden death and can terminate some ventricular tachycardia (VT) without shocks, but they don't prevent VT. The occurrence of ≥1 ICD shock is associated with reductions in mental well-being and physical functioning, and increases in anxiety and sometimes depression. Further, ICD shocks have been consistently associated with adverse outcomes, including heart failure and death. Furthermore, the most important predictor of ICD shocks is a history of prior ICD shocks.\n\nTherapies to suppress VT include antiarrhythmic drug therapy and catheter ablation, neither however is universally effective. When VT recurs despite antiarrhythmic drug therapy and catheter ablation, novel yet invasive, approaches may be required. Such invasive procedures carry consequent risks of cardiac and extra-cardiac injury.\n\nStereotactic body radiotherapy (SBRT) is a non-invasive technique that delivers high doses of radiation precisely to specified regions in the body, while minimizing exposure to adjacent tissue. This technique is currently, and commonly used in the treatment of cancer. Conventional application of SBRT has made use of its ability to spare non-target tissue, including for treatment of tumors near the heart. More recently, clinicians have changed the paradigm, by focusing radioablative energy on ventricular scar responsible for ventricular tachycardia. Pre-clinical studies have supported the concept and were followed by first-in-human VT therapeutic experience in 2017. Subsequent studies have had encouraging results for patients who failed or were unable to tolerate conventional treatment.",[29,256,402],"Heart Disease Structural Disorder","2026-03-16",{"date":405,"type":37},"2026-03-18",{"date":407,"type":37},"2021-06-01",{"date":287,"type":21},{"name":410,"class":81},"John Sapp",{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":130},"100340542","peri-procedural-transmural-electrophysiological-ep-imaging-of-scar-related-ventricular-tachycardia-100340542","NCT03713866","Peri-Procedural Transmural Electrophysiological (EP) Imaging of Scar-Related Ventricular Tachycardia","Peri-Procedural Transmural Electrophysiological Imaging of Scar-Related Ventricular Tachycardia","ECGI-VT","Inclusion Criteria:\n\n* One or more episodes of sustained monomorphic VT\n* Referred for catheter ablation\n* Previously implanted ICD\n* Signed the patient informed consent form\n* Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n\nExclusion Criteria:\n\n* Have estimated Glomerular Filtration Ratio (eGFR) less than 30\n* Have a life expectancy less than 6 months or are listed for heart transplantation at time of inclusion\n* Are pregnant\n* Are on IV inotropic agents\n* Have any contraindication to catheter ablation (including but not limited to mechanical prosthetic aortic and mitral valves, known protruding Left Ventricular (LV) thrombus\n* New York Heart Association (NYHA) functional class IV\n* Had ST wave elevation myocardial infarction within \\\u003C 1 month\n* Unwilling or unable to undergo cardiac MRI scan AND unwilling or unable to undergo cardiac CT scan (e.g. contrast allergy).",{"count":420,"type":21},20,[24],"Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical \"short circuit\" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. An important treatment is to use catheter ablation to \"block\" the channel that forms the circuit. Effective ablation requires imaging guidance to visualize the VT circuit relative to scar structures in 3D. Unfortunately, with conventional catheter mapping, up to 90% of the VT circuits are too short-lived to be mapped. For the 10% \"mappable\" VTs, their data are only available during ablation and limited to one ventricular surface. This inadequacy of functional VT data largely limits the knowledge about scar-related VT and ablation strategies, and reduces the ability of clinicians to identify ablation targets and assess ablation outcome.\n\nThe central hypothesis of this proposal is that functional VT data, integrated with CT or MRI scar data in 3D, can improve VT ablation efficacy with pre-procedural identification of ablation targets and post-procedural mechanistic elucidation of ablation failure. This research builds on the rapidly increasing clinical interest in electrocardiographic imaging (ECGi), an emerging technique that obtains cardiac electrical activity through inverse reconstructions from ECGs. The specific objective is to push the boundary of ECGi to provide - as a conjunction to intra-procedural catheter mapping - pre-ablation and post-ablation imaging of functional VT circuits integrated with 3D scar structure.",[29,256],{"date":425,"type":37},"2026-03-17",{"date":427,"type":37},"2019-11-01",{"date":429,"type":21},"2027-03-31",{"name":410,"class":81},{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":438,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":444,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":454,"locationsCount":130},"100400829","improving-patient-reported-outcome-measures-in-catheter-ablation-100400829","NCT04499326","Improving Patient Reported Outcome Measures in Catheter Ablation","Use of Patient Reported Outcome Measures (PROMs) to Assess Quality of Life and Economic Evaluation of Cardiac Catheter Ablation of Ventricular Tachycardia: a Feasibility and Cohort Study","Inclusion Criteria:\n\nAdults (\\>18 years) With an Implantable Cardioverter Defibrillator (ICD) implanted \\>3 months from time of recruitment and a previous episode of documented VT requiring therapy from the ICD.\n\nAnd impaired LV\u002FRV function Willing and able to give written informed consent\n\nExclusion Criteria:\n\nPatients who are planning to move away from study site within 12 months of enrolment who wished to use postal method to complete their HRQL Patients who are unable to give informed consent",{"count":299,"type":21},[24],"This study will assess whether more frequent measurement of patient reported outcome measures (PROMs) - specifically health related quality of life (HRQL) - can improve the evaluation of the clinical effectiveness and cost-effectiveness of catheter ablation of ventricular tachycardia (VT) in patients with an Implantable Cardioverter Defibrillator (ICD).\n\nIt is designed to have feasibility outcomes which contribute to answering the above.",[29,442,443],"ICD","Quality of Life",[445,446,447],"Catheter ablation","Patient reported outcome measure","Incremental cost effectiveness ratio","2026-02-26",{"date":450,"type":37},"2026-03-02",{"date":360,"type":37},{"date":453,"type":21},"2026-12-31",{"name":455,"class":81},"Barts & The London NHS Trust",{"id":457,"slug":458,"hasResults":12,"nctId":459,"briefTitle":460,"officialTitle":460,"acronym":461,"eligibilityCriteria":462,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":22,"phases":464,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":130},"100543828","radiotherapy-vs-catheter-ablation-for-ventricular-tachycardia-in-structural-heart-disease-100543828","NCT06360939","Radiotherapy vs Catheter Ablation for Ventricular Tachycardia in Structural Heart Disease","RadioAblate-VT","Inclusion Criteria:\n\n1. Structural heart disease (including ischaemic cardiomyopathy , non-ischaemic cardiomyopathy or congenital heart disease and defined as any one of\n\n   1. segmental or global decreased ventricular wall motion as defined by TTE, CT or cMRI\n   2. myocardial hypertrophy\n   3. myocardial scar (evidenced by late gadolinium enhancement on cMRI, wall thinning on cardiac CT, low voltage on electrophysiological study or abnormal intracardiac echocardiography)\n2. Recurrent monomorphic VT which can include\n\n   1. at least one episode of VT treated by ICD and\u002For\n   2. sustained VT (lasting \\>30s) and\u002For\n   3. inducible sustained VT on invasive electrophysiological study (EPS) or non-invasive programmed stimulation (NIPS)\n3. PAINESD score of ≥9 points and\u002For at least moderate risk of VT recurrence or death as defined by the I-VT score. Both are validated tools used clinically to identify patient at high risk of VT recurrence and\u002For mortality after CA.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Life expectancy \\\u003C 3 months\n3. Catheter ablation deemed futile or with prohibitive risk by cardiac electrophysiologist.\n4. Unwilling or unable to provide consent\n5. Known cardiac channelopathies (e.g. Catecholaminergic polymorphic ventricular tachycardia (CPVT), long- or short QT syndrome, Brugada syndrome)\n6. Contraindications to radiotherapy as deemed by referring physician and\u002For radiation oncologist\n7. Pregnancy or breast feeding",{"count":231,"type":21},[24],"The goal of this randomized clinical trial is to test the efficacy of stereotactic body radiation therapy (SBRT) in treating ventricular tachycardia (VT) in patients with advanced structural heart disease. The main questions it aims to answer are:\n\n* What is the efficacy of SBRT compared to catheter ablation (CA) in achieving a ≥ 75% reduction in VT burden at 6 months\n* What is the comparable safety profile of SBRT vs CA Researchers will compare SBRT and CA (standard of care).",[29,200,147,27],[468,469,470,471],"catheter ablation","stereotactic body radiation therapy","non invasive","radioablation","2026-02-15",{"date":474,"type":37},"2026-02-18",{"date":476,"type":37},"2025-11-03",{"date":478,"type":21},"2027-12-20",{"name":480,"class":81},"Western Sydney Local Health District",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":22,"phases":490,"briefSummary":491,"conditions":492,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":501,"lastUpdatePostDateStruct":502,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":508,"locationsCount":510},"100601901","a-study-assessing-arrhythmia-mapping-with-a-multi-electrode-mapping-catheter-100601901","NCT07116525","A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter","Clinical Evaluation of Arrhythmia Mapping With a Paddle-shaped, High-density, Multi-electrode Mapping Catheter","FEATHER","Inclusion Criteria:\n\n* Diagnosed with and candidate for clinically indicated catheter mapping and ablation procedure for the management of ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation (participant having undergone a previous ablation procedure may be included)\n* At least one episode of the targeted arrhythmia (ventricular tachycardia, premature ventricular complex, atrial tachycardia or atrial fibrillation) must have been documented by electrocardiogram (ECG), Holter, loop recorder, telemetry, implanted device, or transtelephonic monitoring within 12 months prior to enrollment\n* Age 18 years or older\n* Signed Patient Informed Consent Form (ICF)\n* Able and willing to comply with all pre-, post-, and follow-up testing and requirements\n\nExclusion Criteria:\n\n* Study arrhythmia secondary to reversible cause, or secondary to electrolyte imbalance, thyroid disease, or non cardiac cause\n* Patients requiring left atrial procedures: left atrial size greater than (\\>) 55 millimeter (mm)\n* Left ventricular ejection fraction(LVEF) less than or equal to (\\\u003C=) 25 percentage (%) for participants with ventricular arrhythmia\n* LVEF \\\u003C= 40% for participants with atrial arrhythmia\n* Documented intracardiac thrombus as detected on imaging within 24 hours prior to insertion of the investigational catheter\n* Contraindication to anticoagulation (that is, heparin, warfarin, dabigatran)\n* History of blood clotting or bleeding abnormalities (example hypercoagulable state)\n* Myocardial infarction within the past 2 months (60 days)\n* Documented thromboembolic event (including transient ischemic attack \\[TIA\\]) within the past 12 months (365 days)\n* Uncontrolled heart failure or New York heart association (NYHA) function class IV\n* Implanted with a pacemaker or intracardiac cardiac defibrillator or appendage closure device within the past 6 weeks (42 days)\n* Patients with known untreatable allergy to contrast media\n* Active illness or active systemic infection or sepsis\n* Diagnosed atrial or ventricular myxoma, interatrial baffle or patch, tumor or other abnormality that precludes catheter introduction or manipulation\n* Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study\n* Participants that have ever undergone a percutaneous or surgical valvular cardiac procedure (that is, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve)\n* Participants that currently have Impella or equivalent devices on the procedure date or up to 7 days prior\n* Any cardiac surgery within the past 60 days (2 months) (includes percutaneous coronary intervention \\[PCI\\])\n* Atrial septal closure within the past 6 weeks (42 days)\n* Presence of a condition that precludes vascular access\n* Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of childbearing age and plan on becoming pregnant during the course of the clinical investigation\n* Categorized as vulnerable population and requires special treatment with respect to safeguards of well-being\n* Concurrent enrollment in an investigational study evaluating another device or drug",{"count":231,"type":21},[24],"The purpose of this study is to assess the safety and feasibility of the investigational catheter for mapping the atrial and ventricular regions of the heart.",[493,494,495,496,29,497,498,499,500,177],"Scar-related Atrial Tachycardia","Persistent Atrial Fibrillation","Paroxysmal Atrial Fibrillation","Ventricular Procedures","Ischemic Ventricular Tachycardia","Non-ischemic Ventricular Tachycardia","Cardiomyopathy","Idiopathic Ventricular Tachycardia","2026-02-12",{"date":503,"type":37},"2026-02-13",{"date":505,"type":37},"2025-09-15",{"date":507,"type":21},"2026-09-30",{"name":509,"class":44},"Biosense Webster, Inc.",6,{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":130},"100573246","trial-in-arrhythmia-radioablation-for-ventricular-tachycardia-single-fraction-vs-three-fractions-100573246","NCT06743789","Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions","Dose De-escalation Randomized Phase I\u002FII Trial in Arrhythmia Radioablation for Ventricular Tachycardia: Single Fraction vs Three Fractions","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Structural heart disease:\n\n  1. Ischemic cardiomyopathy\n  2. Non-ischemic cardiomyopathy\n  3. Hypertrophic cardiomyopathy\n* Refractory VT severity:\n\n  1. VT leading to ICD shock with minimum 3 episodes in any 3-month period without reversible cause;\n  2. Failed or intolerant to antiarrhythmic drug therapy (either amiodarone or ≥ 2 AADs) AND failed ablation (CA)\n  3. OR ablation (CA) contraindicated\n* Ability to understand study protocol and to write informed consent\n* Willing to comply with specified pre-, post- and follow-up testing, evaluations and requirements\n* Expected to remain available for at least 36 months after enrollment\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* Prior chest radiation therapy",{"count":519,"type":21},40,[24],"This is a research study that aims to understand if giving a lower dose of treatment all at once is as effective and safe as dividing it into three smaller doses for patients with a heart condition called refractory ventricular tachycardia (VT). These patients have not exhibited positive responses to conventional medications or procedures. This study aims to explore whether an alternative approach could yield more beneficial outcomes.",[29],"2026-01-22",{"date":525,"type":37},"2026-01-26",{"date":527,"type":37},"2024-12-18",{"date":529,"type":21},"2030-12",{"name":531,"class":81},"Weill Medical College of Cornell University",{"id":533,"slug":534,"hasResults":12,"nctId":535,"briefTitle":536,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":541,"conditions":542,"keywords":544,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":557,"locationsCount":130},"100472987","phase-2-stereotactic-arrhythmia-radiotherapy-in-the-netherlands-no-2-100472987","NCT05439031","StereoTactic Arrhythmia Radiotherapy in the NetherLands no. 2","STARNL-2","Inclusion Criteria:\n\n* Age ≥18 years\n* Implanted ICD\n* World Health Organization (WHO) \u002F Eastern Cooperative Oncology Group (ECOG) performance status grade 0-3 in the past 3 months (from fully active to capable of limited self-care, see below for full explanation)\n* At least 3 episodes of treated VT within the last 3 months\n* Recurrence of VT after\n\n  * Failed or intolerant to least one class 1 or class 3 anti-arrhythmic drug AND\n  * At least one catheter ablation procedure OR considered to be unsuitable for a catheter ablation procedure (e.g. no sufficient vascular access, considered unfit to undergo prolonged general anesthesia, comorbid conditions resulting in unacceptable peri-procedural risks)\n* Able and willing to undergo all necessary evaluations, treatment and follow-up for the study and of follow-up thereafter\n\nExclusion Criteria:\n\n* Pregnancy\n* History of radiation treatment in the thorax or upper abdominal region\n* Interstitial pulmonary disease",{"count":398,"type":21},[326],"Ventricular tachycardia (VT) is a malignant cardiac arrhythmia subjecting our patients to a high risk of sudden death, increased morbidity and reduced quality of life. Unfortunately, failure of treatment is common and VT recurrences remain an important concern. In these patients, stereotactic arrhythmia radiotherapy appears to be an effective and safe treatment. The mechanism of action however remains unknown and should be elucidated.\n\nThe objective of this phase 2, single arm, monocenter, pre-post intervention study is to evaluate the efficacy and safety of stereotactic arrhythmia radiotherapy and obtain insights in the mechanism of action by evaluating electro-anatomical alterations of stereotactic arrhythmia radiotherapy in patients with therapy refractory ventricular tachycardia.",[29,543],"Arrythmia, Cardiac",[545,29,546,547,548,549,550],"Ventricular Arrhythmias","Cardiac Radioablation","Stereotactic Radiotherapy","Stereotactic Arrhythmia Radiotherapy","Stereotactic body radiotherapy","Cardiac ablative radiotherapy","2026-01-13",{"date":553,"type":37},"2026-01-14",{"date":555,"type":37},"2023-05-19",{"date":102,"type":21},{"name":558,"class":81},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":570,"conditions":571,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":578,"locationsCount":82},"100481038","vt-ablation-in-the-icmr-100481038","NCT05543798","VT Ablation in the iCMR","Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia","VISABL-VT","Inclusion Criteria:\n\n* Roll-in subjects only: Documentation of premature ventricular contractions indicated for ablation therapy (subjects may or may not be diagnosed with Ischemic Cardiomyopathy)\n* Documented (ECG\u002FEGM) spontaneous episode of sustained ventricular tachycardia within 6 months of the procedure\n* Diagnosis of Ischemic Cardiomyopathy\n* AAD therapy refractory, contraindicated, not tolerated, or not desired\n* 18 years or older\n\nExclusion Criteria:\n\n* Implanted with non-MR compatible medical devices or contraindicated for an MRI\n* Presence of intracardiac thrombus (verified via CT\u002FMRI\u002FTEE\u002FTTE within 48 hours of procedure - or at start of procedure)\n* Thrombocytopenia or coagulopathy\n* Mechanical mitral and\u002For aortic valve precluding access to the left ventricle\n* Severe aortic stenosis\n* Myocardial infarction requiring stent implantation within 90 days of procedure\n* Previous cardiac surgery within 60 days of procedures\n* Known\u002Funcontrolled stroke risks\n* Class IV Heart Failure\n* Ejection Fraction (EF) \\\u003C 25%\n* Patients with a glomerular filtration rate (GFR) \\\u003C 30\n* Women who are pregnant\n* Allergy to contrast agents (e.g., Gadolinium)\n* Active infection\n* Known or suspected myxoma\n* Unstable angina\n* Patients who do not tolerate anticoagulation therapy\n* Previous intertribal septal patch or prosthetic atrial septal defect closure device\n* Life expectancy \\\u003C 12 months\n* Enrollment in another study without sponsor approval",{"count":568,"type":21},64,[24],"The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.",[29],"2026-01-06",{"date":574,"type":37},"2026-01-08",{"date":576,"type":37},"2025-04-10",{"date":362,"type":21},{"name":579,"class":44},"Imricor Medical Systems",{"id":581,"slug":582,"hasResults":12,"nctId":583,"briefTitle":584,"officialTitle":584,"acronym":585,"eligibilityCriteria":586,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":587,"targetDuration":4,"studyType":22,"phases":589,"briefSummary":591,"conditions":592,"keywords":594,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":601,"lastUpdatePostDateStruct":602,"startDateStruct":604,"completionDateStruct":606,"leadSponsor":608,"locationsCount":130},"100537757","phase-3-study-evaluating-dexmedetomidine-in-the-acute-treatment-of-electrical-storm-100537757","NCT06281977","Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm","SEDATE","Inclusion Criteria:\n\n\\- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.\n\nExclusion Criteria:\n\n* Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors\n* SCAI class D or E cardiogenic shock\n* Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.\n* ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.\n* Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.\n* Pregnancy\n* Known dexmedetomidine allergy or intolerance\n* Inability to obtain consent from patient or substitute decision maker.\n* Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization",{"count":588,"type":21},192,[590],"PHASE3","The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.",[29,545,28,593],"Recurrent Ventricular Tachycardia",[595,596,597,598,599,593,600],"Electrical Storm","Dexmedetomidine","Ventricular Electrical Storm","Precedex","Recurrent Ventricular Arrhythmias","Sedation","2025-12-16",{"date":603,"type":37},"2025-12-17",{"date":605,"type":37},"2024-05-08",{"date":607,"type":21},"2027-08-01",{"name":609,"class":81},"Ottawa Heart Institute Research Corporation",{"id":611,"slug":612,"hasResults":12,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":12,"sex":17,"minAge":617,"maxAge":4,"enrollmentInfo":618,"targetDuration":4,"studyType":22,"phases":620,"briefSummary":621,"conditions":622,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":130},"100612987","evaluation-of-a-single-lead-ecg-patch-based-telemetry-system-for-in-hospital-monitoring-100612987","NCT07260721","Evaluation of a Single-lead ECG Patch-based Telemetry System for In-hospital Monitoring","Investigator-initiated Trial to Evaluate the Performance and Utility of a Single-lead Electrocardiogram Patch-based Telemetry System in Patients Requiring In-hospital Telemetry Electrocardiogram Monitoring During Hospitalization","Inclusion Criteria:\n\n* Adults aged 19 years or older who provide written informed consent for participation.\n* Patients requiring in-hospital telemetry electrocardiogram monitoring during hospitalization.\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergic reaction to adhesives or hydrogel.\n* Presence of skin wounds at the intended application site of the investigational device.\n* Implanted cardiac electronic devices such as pacemakers, ICDs, or other CIEDs\n* Current or past history of skin cancer, rash, dermatologic disorders, keloid formation, or skin injury.\n* Any condition judged by the investigator to increase risk or make participation inappropriate.\n* Cognitive impairment that precludes understanding of study information or voluntary consent.","19 Years",{"count":619,"type":21},100,[24],"\"This investigator-initiated, prospective, single-center clinical study evaluates the performance and clinical utility of a single-lead electrocardiogram (ECG) patch-based telemetry system for hospitalized patients who require in-hospital telemetry ECG monitoring. The system integrates real-time centralized surveillance (MEMO-Cue) with post-hoc analytic review (MEMO-Care) using ECG signals recorded by the MEMO Patch M, aiming to enable timely recognition of clinically important arrhythmias and to inform treatment decisions under routine inpatient conditions.\n\nAdults (≥19 years) indicated for continuous ECG monitoring during admission are enrolled after written informed consent, with a planned sample size of 100 to yield approximately 90 evaluable participants (10% anticipated dropout). The design does not include randomization or blinding. Study procedures include a screening visit (eligibility and baseline data), an inpatient monitoring period of at least 12 hours and up to 8 days with simultaneous MEMO-Cue monitoring and MEMO Patch M recording, and an end-of-visit assessment when MEMO-Care analytic results become available. Concomitant therapies deemed clinically necessary are permitted and documented, and adverse events are prospectively assessed.\n\nClinical utility endpoints quantify care impact and timeliness: (1) rate of treatment plan changes (e.g., initiation or modification of anticoagulants or antiarrhythmic drugs, cardioversion scheduling, device implantation, or other actions); (2) time to recognition (days) of major arrhythmias-atrial fibrillation (AF), ventricular tachycardia (VT), pause, ventricular premature complex (VPC), and supraventricular tachycardia (SVT)-based on MEMO-Cue alarms or MEMO-Care results with objective confirmation; (3) reduction ratio in recognition time when identified earlier by MEMO-Cue versus MEMO-Care; and (4) proportion of participants with shortened recognition time by MEMO-Cue.\n\nClinical performance endpoints assess detection characteristics and agreement between MEMO-Cue alarms and MEMO-Care findings: (1) clinical sensitivity (true positive \u002F \\[true positive + false negative\\]); (2) precision, i.e., positive predictive value (true positive \u002F \\[true positive + false positive\\]); and (3) positive concordance rate (proportion of MEMO-Care-detected arrhythmias alerted by MEMO-Cue). Safety is captured as treatment-emergent adverse events after device application, including device-related skin reactions, detachment, or signal dropouts, with severity graded per NCI-CTCAE v5.0 and relationship to device recorded.\n\nBy characterizing real-time patch-based telemetry alongside analytic review and its influence on diagnostic timing and management, the study aims to generate practical evidence supporting feasibility, reliability, and workflow compatibility of single-lead patch telemetry for in-hospital ECG monitoring.",[623,176,29,624,625,626,627,628],"Arrhythmias","Supraventricular Tachycardia","Bradycardia","Telemetry","Patient Monitoring","Hospitalization","2025-12-01",{"date":631,"type":37},"2025-12-03",{"date":633,"type":21},"2025-12",{"date":635,"type":21},"2026-09",{"name":637,"class":81},"Yonsei University"]